Table 1 Patient demographics
Camicinal | |||
|---|---|---|---|
Placebo | 50 mg | 75 mg | |
N = 12 | N = 15 | N = 6 | |
Age in years, mean (SD) | 46 (17) | 63 (17) | 42 (14) |
Sex, n (%) | |||
Female: | 2 (17) | 6 (40) | 1 (16) |
Male: | 10 (83) | 9 (60) | 5 (83) |
BMI (kg/m2), mean (SD) | 28.8 (5.8) | 29.0(6.2) | 28.7 (3.7) |
Height (cm), mean (SD) | 173 (8) | 172 (10) | 178 (9) |
Weight (kg), mean (SD) | 86 (17) | 86 (20) | 91 (17) |
Baseline renal function | |||
Baseline creatinine (μmol/L), mean (SD) | 73.1 (33) | 89.3 (84) | 56.0 (7.3) |
Baseline hepatic function | |||
ALT (IU/L), mean (SD) | 44.6 (30) | 34.7 (22) | 58.3 (39) |
AST (IU/L), mean (SD) | 43.2 (23) | 35.6 (19) | 55.2 (39) |
Total bilirubin (μmol/L), mean (SD) | 10.5 (15) | 10.2 (13) | 5.7 (3.7) |
Admission category, n (%) | |||
Trauma | 5 (42) | 4 (27) | 1 (17) |
Head injury | 1 (8) | 3 (20) | 1 (17) |
Respiratory failure | 1 (8) | 3 (20) | 0 |
Sepsis | 2 (17) | 2 (13) | 0 |
Other | 3 (25) | 3 (20) | 4 (67) |
Illness severity and duration | |||
APACHE II, median (min, max) | 17.5 (6, 37) | 19 (5, 30) | 14 (7, 29) |
Days in ICU prior to enrollment, median (min, max) | 4 (1, 9) | 4 (2, 19) | 4.5 (1, 7) |
Days in ICU prior to study, median (min, max) | 5 (2, 10) | 5.5 (2, 9) | 5 (2, 19) |
Days in hospital prior to study, median (min, max) | 5 (2, 10) | 7 (3, 26) | 5.5 (3, 9) |
Concomitant chronic illnesses, n | |||
Diabetes | 3 | 0 | 0 |
Concomitant medications, n | |||
Catecholamines | 2 | 6 | 1 |
Opioids/opiates | 12 | 14 | 4 |
Muscle relaxant | 3 | 3 | 0 |
EN prior to enrollment | |||
Time from starting EN to development of feed intolerance; hours median (min, max) | 29 (3, 162) | 55 (5, 396) | 50 (8, 81) |
EN administered (EN delivered – discarded) in 24 hours prior to study eligibility; mL, median (min, max) | 1130 (415, 1547) | 950 (140, 1920) | 904 (305, 1388) |